Navigation Links
MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
Date:10/29/2007

SAN FRANCISCO, Oct. 29 /PRNewswire/ -- MedImmune today announced results from a recent economic analysis of Synagis(R) (palivizumab), a monoclonal antibody (MAb) that is the standard of care for prevention of severe lower respiratory tract infection due to respiratory syncytial virus (RSV) in high- risk infants. Released at the American Academy of Pediatrics (AAP) 2007 National Conference & Exhibition, the analysis evaluated the costs of providing Synagis to premature infants, as well as the potential health benefits and cost savings that could occur from lower rates of severe RSV infections.

RSV can cause severe lower respiratory tract infections in preterm infants. However, recent data have suggested that RSV infection early in an infant's life may cause subsequent chronic respiratory complications such as persistent wheezing.

Dr. Mark Polak, a neonatologist and professor of pediatrics from the West Virginia University School of Medicine and lead author of the economic analysis, noted, "We factored in the potential costs of possible future complications and the quality of life associated with persistent wheezing and, based on these assumptions, our study found that preventing RSV early in life makes economic sense."

The authors noted that more evidence is needed to substantiate the linkage between Synagis and subsequent reductions in persistent wheezing.

MedImmune's Commitment to RSV Prevention

MedImmune is a world leader in the development of innovative therapeutic biologic products to prevent RSV disease. In 1996, MedImmune launched the first anti-RSV drug, RespiGam(R) (respiratory syncytial virus immune globulin intravenous (human) (RSV-IGIV)), which was a polyclonal antibody administered via four-hour intravenous infusion. In 1998, MedImmune introduced Synagis, which was a significant product improvement as a monthly intramuscular injection for the prevention of severe RSV, as well as being the first MAb to receive U.S. Foo
'/>"/>

SOURCE MedImmune
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
9. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
10. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  MEDIMETRIKS PHARMACEUTICALS today ... William Resnick have been elected to Medimetriks, ... Mr. Lary, who will serve on Medimetriks, ... investment experience to the Company.  Mr. Lary is ... LLC, a leading institutional investment firm.  Mr. Lary ...
(Date:9/23/2014)... 2014  Vesselon, Inc. today announced the appointment of ... September 15, 2014. Dr. Raths, appointment follows Vesselon,s engagement ... to market a private preferred Series A round to ... "Jurgen,s deep experience across multiple functional areas ... to Vesselon as we develop our device that can ...
(Date:9/23/2014)... 23, 2014  KemPharm, Inc., a clinical-stage specialty ... of proprietary new molecular entity (NME) prodrugs, announced ... (NOL) from Health Canada to begin clinical trials ... lead product candidate KP201 (benzhydrocodone hydrochloride and acetaminophen).  ... acute moderate to moderately severe pain. The Health ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3
... 7 Genomic Health,Inc. (Nasdaq: GHDX ) ... the,company,s Oncotype DX(R) breast cancer test are scheduled ... Breast Cancer Symposium, taking place,December 13-16, 2007. Oncotype ... to predict the likelihood of recurrence and the ...
... PROCRIT(R) (Epoetin alfa),studies will be presented at the American Society of ... The data will provide important insights including:, ... limiting the use of erythropoiesis-stimulating agents (ESAs) ... -- the use of PROCRIT in extended dosing regimens; ...
Cached Medicine Technology:Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 2Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 3PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 2PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 3PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 4PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 5PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 6PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 7PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 8PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 9
(Date:9/23/2014)... The Sloane Clinic™, a leading ... Malaysia providing advanced aesthetic dermatology and cosmetic solutions ... impressive skin care repertoire. Specially formulated with super-powered ... the evil forces of aging, acne and photo ... new addition is revolutionizing the way we treat ...
(Date:9/23/2014)... September 23, 2014 The University ... research university located In the Piedmont Triad, announced ... as co-director of the Center for Translational Biomedical ... comes to UNCG after nearly a decade at ... Laboratory, Biological Sciences Division. , “Our goal ...
(Date:9/23/2014)... HealthDay Reporter MONDAY, ... marches demanding action on climate change, a new study ... the United States may soon exacerbate many existing health ... illnesses are expected to increase as the number of ... Patz, director of the Global Health Institute at the ...
(Date:9/23/2014)... Randy Dotinga HealthDay Reporter ... using cholesterol-lowering drugs while in the hospital for a hemorrhagic ... more than four times more likely to survive than people ... People taking the commonly used drugs known as statins ... or to a rehabilitation facility, the study reports. When ...
(Date:9/23/2014)... Hospital Medical Center have published the first study ... published in The Journal of Allergy and ... systemic disorder that has high levels of eosinophils ... series of allergy-associated-immune mechanisms and has a gene ... of a related disorder, eosinophilic esophagitis (EoE). ...
Breaking Medicine News(10 mins):Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:Former Department of Energy Scientist Joins UNCG as Co-director of Biomedical Research Center 2Health News:Health Woes to Worsen Due to Climate Change, Study Warns 2Health News:Health Woes to Worsen Due to Climate Change, Study Warns 3Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 2Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 3Health News:Advancing the understanding of an understudied food allergy disorder 2Health News:Advancing the understanding of an understudied food allergy disorder 3
... well, sports commentators may describe them as being "hot" or ... the eye of the beholder, but a new study by ... that a streak of positive outcomes is likely to continue., ... the study analyzed five years of NBA free throws that ...
... HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay News) -- Older ... a greater risk of developing dementia than folks who believe ... the journal Neurology . Someday, "having people rate ... to determine a person,s risk of dementia, especially for people ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Oct. ... forms of multiple sclerosis appears to reduce relapse rates and ... 3 trial. The experimental drug, teriflunomide, is one of ... and may, if approved, be a good choice for many ...
... Oct. 5 (HealthDay News) -- The percentage of nursing ... flu shot is lower than the national goal, and the ... study finds. Brown University researchers examined annual patient records ... 2006-07 to 2008-09. The overall flu vaccination rate for ...
... , WEDNESDAY, Oct. 5 (HealthDay News) -- Nearly one in ... center than 10 years ago due to closures of hospital ... had the greatest impact on black people, the poor, the ... San Francisco researchers. "Trauma centers aren,t just for ,certain, ...
... life experiences -- the ups and downs, and everything in ... emotional set point as adults, according to a new study ... suggests that, in addition to our genes, our life experiences ... "In this time of emphasis on genes for this ...
Cached Medicine News:Health News:Athletes' winning streaks may not be all in our -- or their -- heads 2Health News:Gauging General Health as 'Poor' May Point to Dementia Risk 2Health News:Experimental MS Drug Shows Promise 2Health News:Experimental MS Drug Shows Promise 3Health News:Nursing Homes Not Meeting Flu-Shot Goals, Study Says 2Health News:More Americans Face Longers Trips to ER 2Health News:Virginia Commonwealth University study: We are what we experience 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: